Share information
274.90 €
+1.44 %
12/06/2026 17:35
+1.44 %
Open
High
Low
Volume
269.30 €
275.50 €
264.70 €
169,042
Latest News
05-Jun-2026
New EULAR 2026 data show CIMZIA[®] (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels
04-Jun-2026
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
03-Jun-2026
BIMZELX[®](bimekizumab) data at EULAR 2026 show early and sustained inflammation control can improve patient reported outcomes and limit disease progression in PsA and axSpA
02-Jun-2026
UCB presents research at EUROMIT 2026 highlighting burden of care, need for earlier diagnosis, and impact of pyrimidine nucleoside therapy on people living with TK2d